Rising levels of cytomegalovirus (CMV) DNAemia and/or pp65 antigenemia have been observed during pre-emptive ganciclovir therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). We assessed the incidence of this event in our series, and investigated whether its occurrence was associated with an impairment in the CMV-specific T-cell response. A total of 36 allo-SCT recipients experienced one or more episodes of active CMV infection (n ¼ 68) that were preemptively treated with val(ganciclovir). Rising levels of antigenemia and DNAemia, and an isolated increase in antigenemia, were observed in 39.7 and 2.9% of all episodes, respectively. Receipt of corticosteroids was associated with rising levels of antigenemia and DNAemia. Median increases of 12-and 6.8-fold of IFNc CD8 þ T and IFNc CD4 þ T cells, respectively, were observed at a median of 16.5 days after initiation of therapy in episodes with decreasing levels in antigenemia and DNAemia. In contrast, the numbers of both T-cell subsets at a median of 13.5 days after initiation of therapy did not differ significantly from those of pre-treatment samples in episodes with rising levels of antigenemia and DNAemia. Lack of prompt expansion of CMV pp65 and IE-1-specific IFNc CD8 þ and CD4 þ T cells is associated with rising levels in antigenemia and DNAemia during pre-emptive therapy.
Introduction
The pp65 antigenemia assay is widely used for guiding and monitoring the efficacy of pre-emptive therapy for active cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant (allo-SCT) recipients. Preemptive therapy results in most cases in a rapid decline of antigenemia until complete clearance. Nevertheless, increasing levels in antigenemia early after initiation of ganciclovir treatment has been reported to occur with certain frequency in this clinical setting. [1] [2] [3] Two distinct patterns of rising antigenemia have been observed: a simultaneous increase in both antigenemia and DNAemia levels, and an isolated increase in the antigenemia level with decreasing or stable DNAemia levels. The former pattern is seen mainly in patients on treatment with high-dose steroids for graft versus host disease (GvHD), 2, 3 or in those receiving antithymocyte globulin (ATG) in the conditioning regimen. 4 As both drugs are known to cause immunosuppression, a failure in building up a prompt functional T-cell response to CMV is the most likely explanation accounting for the occurrence of these episodes. This assumption, nevertheless, has not been shown. Rising levels in antigenemia and DNAemia may also be due to the emergence of ganciclovir-resistant strains; this phenomenon, however, does not seem to be frequent in the allo-SCT setting. 5 The latter pattern was documented earlier in solid-organ transplant recipients experiencing a primary CMV infection and its pathogenetic basis was later elucidated. 6, 7 It was shown that persistence of antigenemia in the absence of DNAemia when on ganciclovir treatment was due to overproduction of pp65. 7 No risk factors seem to be significantly associated with such episodes of active CMV infection in allo-SCT recipients, the resolution of which does not require modification of ongoing antiviral therapy. 3 In an earlier study, we showed that CMV pp65 and IE-1-specific IFNg-producing CD8 þ and CD4
þ T cells provide protection against CMV viremic infection. 8 In this study, we report on the frequency of the different antigenemia kinetic patterns observed during preemptive antiviral therapy in our setting and investigated whether a lack of expansion of CMV pp65 and IE-1-specific IFNg CD8 þ and CD4 þ T in response to virus replication was associated with rising levels of antigenemia and DNAemia during pre-emptive therapy. At present, there are no consensus criteria for the therapeutic management of such episodes of active CMV infection. Immunological data presented in this study may contribute to define the optimal strategy for their treatment.
Patients and methods

Patients
Patients undergoing allo-SCT between January 2006 and July 2008 at the Hospital Clı´nico Universitario, Valencia; Hospital La Princesa, Madrid; Hospital Ramo´n y Cajal, Madrid; and Hospital Morales Meseguer, Murcia were eligible for inclusion. The study was approved by the Ethics Committees. All patients gave their informed consent to participate in the study.
Virological monitoring and management of active CMV infection
Patients were monitored for pp65 antigenemia by a commercial immunofluorescence assay (Light Diagnostics CMV pp65 Antigenemia Immunofluorescence assay, Chemicon International, Temecula, CA, USA) and plasma DNAemia (CMV real-time polymerase chain reaction (PCR), Abbott Molecular, Des Plaines, IL, USA or AMPLICOR CMV Monitor, Roche, Indianapolis, IN USA) once a week until day þ 100, and every other week thereafter until day þ 180 as described earlier. 9, 10 Virological monitoring beyond this time point was performed at each routine clinical control, and when clinical signs compatible with CMV end-organ disease were present. During episodes of active CMV infection, both tests were performed two or three times a week. For data analysis, the commencement of a given episode was defined by a simultaneous positive result for both the PCR and the antigenemia assays. The end of a given episode was defined by a simultaneous negative result for both tests. A relapsing episode was defined by the reappearance of antigenemia and/or DNAemia after the end of the preceding episode. Pre-emptive therapy with oral valganciclovir (900 mg/12 h) or i.v. ganciclovir (5 mg/kg/12 h) was initiated on a positive antigenemia result (X1 pp65 positive cells/200 000 cells). Pre-emptive therapy was discontinued after two consecutive negative antigenemia results obtained 3 days apart, after a minimum of 2 weeks of treatment. Maintenance doses of valganciclovir (450 mg/12 h) were given to some patients on steroids therapy for GvHD after resolution of the episode of active CMV infection and to a number of patients with persistent DNAemia after antigenemia clearance. Foscarnet (i.v. 60 mg/kg/12 h) was used instead of ganciclovir in patients with severe neutropenia. In some instances, foscarnet was added to the therapy schedule or replaced ganciclovir or valganciclovir after initiation of pre-emptive therapy when the antigenemia assay continued to be positive beyond the third week of treatment. CMV end-organ disease was diagnosed and treated as reported earlier. 9, 10 Immunological monitoring Enumeration of CMV-specific IFNg-producing CD8 þ and CD4 þ T lymphocytes was carried out by flow cytometry for ICS (BD Fastimmune, BD-Beckton Dickinson and Company-Biosciences, San Jose, CA, USA) as described earlier.
8 Briefly, 0.5 ml of heparinized whole blood was simultaneously stimulated with two sets of 15-mer overlapping peptides encompassing the sequence of pp65 and IE-1 CMV proteins (2 mg/ml per peptide), obtained from JPT peptide Technologies GmbH (Berlin, Germany), in the presence of 1 mg/ml of costimulatory mAbs to CD28 and CD49d. Samples mock stimulated with PBS/DMSO and costimulatory antibodies were run in parallel. Brefeldin A (10 mg/ml) was added for the last 4 h of incubation. Blood was then lysed and frozen at À80 1C until tested. On the day of testing, stimulated blood was thawed at 37 1C, washed, permeabilized, and stained with a combination of labeled moAbs (anti-IFNg-FITC, anti-CD69-PE, anti-CD4 or CD8-PerCP-Cy5.5, and anti-CD3-APC when the IFNg CD8 þ kit was used) for 30 min at room temperature. Appropriate isotype controls were used. Cells were then washed, resuspended in 200 ml of 1% paraformaldehyde in PBS, and analyzed within 2 h on an FACSCalibur flow cytometer using CellQuest software (BD Biosciences Immunocytometry Systems, San Jose, CA, USA). Data files usually contained at least 1000 positive events for CD4 þ or CD8 þ within the lymphocyte gate. CD4 þ and CD8 þ events were gated and then analyzed for the CD69 activation marker and IFNg production. The total number of CMV-specific CD4 þ and CD8 þ T cells was calculated by multiplying the percentages of CMV-specific T cells producing IFNg on stimulation (after background subtraction) by the absolute CD4 þ and CD8 þ T-cell counts. The specific responses were considered to be those 40.1% for both CD4 þ and CD8 þ T cells.
Sequence analysis of the UL54 and UL97 genes CMV DNA extraction from plasma specimens was carried out using the High Pure nucleic acid Kit (Roche Diagnostics, GmbH, Mannheim, Germany). The extracted viral DNA was used as a template for amplification of a 975-bp region of the UL97 gene spanning codons 429-753, after an earlier published protocol, 11 and two regions of the UL54 gene spanning codons 345-625 and 645-1013, after an earlier reported nested PCR protocol. 12 The PCR products were purified by the QIAquick purification kit (Qiagen GmbH, Hilden, Germany), sequenced by the ABI Prism BigDye Terminator Cycle Sequencing Kit v3.1 (PE Applied Biosystems, Foster City, CA, USA), and analyzed on an ABI 310 automated DNA sequencer.
Statistical analysis
The statistical significance of differences in medians was assessed by using the Mann-Whitney U-test for unpaired data, and the Wilcoxon's test for paired data. The Fisher's Antigenemia in allo-SCT and CMV-specific immunity N Tormo et al exact test was used to compare dichotomous variables between groups. All tests were two tailed. A Pvalue ¼ o0.05 was considered statistically significant. The statistical analysis was performed with the aid of the statistical package SPSS (version 14.0).
Results
Kinetic patterns of antigenemia and DNAemia during preemptive antiviral therapy A total of 47 out of 76 allo-SCT recipients experienced one or more episodes of active CMV infection (n ¼ 81). Eleven patients developed DNAemia positive/antigenemia negative episodes (n ¼ 13) that were not pre-emptively treated. Thirty-six out of 47 allo-SCT recipients had one or more episodes of active CMV infection (n ¼ 68) that were treated pre-emptively with valganciclovir or ganciclovir. The relevant data of patients treated pre-emptively are summarized in Table 1 . Patients were followed up for a median of 251 days (range, 51-819 days). Forty-three episodes (67.4%) developed within the first 100 days after transplantation. Seventeen patients (47.2%) experienced episodes of active CMV infection in which declining levels of both antigenemia and DNAemia were observed early after initiation of pre-emptive therapy (type A episodes). Twelve patients (33.3%) developed episodes of active CMV infection in which both the antigenemia and DNAemia levels increased during pre-emptive therapy (type B episodes). Five patients (13.8%) experienced both types of episodes during the follow-up. Episodes of active CMV infection with dissociated antigenemia/DNAemia levels (type C episodes) were seen in two patients (5.5%). In summary, out of the 68 episodes, 39 were type A (57.3%), 27 type B (39.7%), and 2 type C (2.9%).
Features of episodes of active CMV infection with either rising or declining levels of antigenemia A median of a 10-fold (range, 2-105-fold) increase in the antigenemia level from baseline (initial positive value) was observed in type B episodes, a median of 13 days (range, 3-71 days) after initiation of therapy. The peak antigenemia level was reached more frequently (51.8%) within the second week. The median increase in DNAemia was 15-fold (range, 2-5969-fold), a median of 14 days (range, 3-171 days) after initiation of therapy. The peak DNAemia occurred most frequently (44.4%) within the second week. As shown in Table 2 , overall, the duration of type B episodes was significantly longer than that of type A episodes. Likewise, peak levels of antigenemia and DNAemia were significantly higher in type B episodes than in type A episodes (except if only initial episodes were considered for analysis). The first positive values for the antigenemia and DNAemia were nevertheless comparable for type A and type B episodes (PX0.5).
Twenty episodes (10 type A and 10 type B) occurred in patients when on maintenance therapy with valganciclovir. These episodes tended to have a longer duration and reached higher peak levels of antigenemia and DNAemia than those developing in its absence. However, these differences did not reach statistical significance, except for duration of DNAemia and peak antigenemia levels in type B episodes (not shown).
Twelve out (9 type B and 3 type A) of the 20 episodes developing when on maintenance therapy occurred in patients under corticosteroid treatment for GvHD. Overall, ongoing treatment with corticosteroids was significantly associated (P ¼ 0.028) with the occurrence of type B episodes. 
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Relapsing CMV infections developed with comparable frequencies (PX0.5) irrespective of whether the initial episode was either type A (38.4%) or type B (40.9%).
CMV-specific T-cell response in episodes of active CMV infection with either decreasing or rising levels in antigenemia and DNAemia
Data on CMV pp65 and IE-1-specific IFNg CD8 þ and CD4 þ T-cell responses obtained before and after initiation of pre-emptive antiviral therapy were available for 24 episodes of active CMV infection (14 type A and 10 type B). These episodes occurred at a median of 46 days after transplant (range, 24-310 days) and were initial episodes in 18 cases and relapses in the remaining six cases. Two type A and four type B episodes developed in patients when on corticosteroid therapy. Data are depicted in Figure 1 . Pre-treatment levels of both T-cell subsets did not differ significantly between type A and type B episodes (PX0.926 and P ¼ 0.862 for IFNg CD8 þ and IFNg CD4 þ T cells, respectively). These samples had been obtained a median of 9 days (range, 0-27 days) and 10.5 days (range, 1-24 days) for type A and type B episodes, respectively (PX0.5), before initiation of pre-emptive antiviral therapy. A significant expansion of both IFNg CD8 þ and IFNg CD4 þ T cells occurred in type A episodes obtained a median of 16.5 days (range, 6-46 days) after initiation of therapy. The duration of the antigenemia and DNAemia in these episodes was 9.5 and 10.5 days, respectively. A 12-fold median increase of IFNg CD8 þ T cells (median, 1.42 cells/ml and range, 0.29-9.46 cells/ml) and a 6.8-fold median increase of IFNg CD4 þ T cells (median, 0.68 cells/ ml and range, 0.17-2.56 cells/ml) were observed. In contrast, in type B episodes, the numbers of both T-cell subsets at a median of 13.5 days (range, 6-122 days) after initiation of therapy did not differ significantly from those of pretreatment samples. In these episodes, the peak levels of antigenemia and DNAemia were reached at a median of 14 days after commencement of pre-emptive therapy. In fact, a modest expansion of the IFNg CD8 þ T-cell subset (median increase of 0.22 cells/ml and range, 0.02-1.97 cells/ml) and IFNg CD4 þ T-cell subset (median increase of 0.24 cells/ml and range, 0.24-0.46 cells/ml), respectively, was showed in only 4 and 3 out of 10 episodes analyzed, respectively. Follow-up monitoring for CMV pp65 and IE-1-specific IFNg CD8
þ and IFNg CD4 þ T-cell levels was available for seven type B episodes in six patients (Table 3 ). In five of these episodes (patients 1, 2, 4 (first episode), 5, and 6), control of CMV replication seemed to be associated with a significant (P ¼ 0.01) increase in both T-cell subsets (except for IFNg CD4 þ T cells in patient 6). In contrast, a failure to expand both T-cell populations was related to the persistence of antigenemia and DNAemia until the end of the follow-up period (patient 3, and patient 4 (second episode)). Relapsing infections developed after 6 episodes (2 type A and 4 type B) out of the 24 episodes for which immunological data were available. Post-treatment levels of IFNg CD8
þ and IFNg CD4 þ T were significantly lower (P ¼ 0.001) in these 6 episodes (median, 0.59 cells/ml and 0.15 cells/ml, respectively) than in the 18 episodes not followed by a relapsing infection (median, 1.97 cells/ml and 0.71 cells/ml, respectively).
Occurrence of CMV-resistant mutations to ganciclovir PCR sequencing of the CMV UL97 and UL54 genes was retrospectively performed on 12 plasma samples obtained during episodes with rising levels of antigenemia and DNAemia (11 type B episodes and 1 type C episode) at the time peak DNAemia values were reached. Mutations in the UL 97 gene conferring resistance to ganciclovir were found in two samples drawn within two type B episodes in two patients (M460I in one sample and deletions in codons 597, 598, 599 in the other sample). These episodes were still active at the end of follow-up (both patients died) and they were not cleared even after the administration of foscarnet (no mutations conferring resistance to foscarnet were detected). In both patients, emergence of resistant strains was detected after 40 and 56 days of maintenance therapy, respectively. An impairment in the CMV-specific T-cell response was observed in both cases during the entire duration of the episode (not shown).
Discussion
In our series, decreasing levels of antigenemia and DNAemia early after initiation of pre-emptive antiviral therapy (type A episodes) was observed in more than half of all episodes of active CMV infection, whereas rising levels of antigenemia and DNAemia were detected in around 40% of cases. These figures are comparable to those reported in earlier studies, 2, 3 in which initial but not relapsing episodes of active CMV infection were taken into consideration. A dissociation between the levels of antigenemia and DNAemia (type C episodes) was only shown in two episodes. Our data are in keeping with those reported by Nichols et al., 2 and Boeckh, 13 but are strikingly different from those published by Gerna et al. 3 In the latter study, 31.4% of episodes (patients) had isolated antigenemia increases. The explanation for this discrepancy is uncertain. It is unlikely that differences in either clinical or demographic characteristics between patients in the two series were responsible. It is also unlikely that the use of a different specimen for CMV DNA quantitation (plasma in our study, whole blood in theirs) accounted for the discrepancy, despite the fact that plasma CMV DNA levels are consistently lower than those found in whole blood. 14 With respect to type B episodes, including those occurring in patients when on maintenance therapy, our observations are in accordance with those reported in earlier studies. 2, 3 Likewise, the receipt of corticosteroids for treatment of GvHD was found to be significantly associated with the occurrence of type B episodes, as was reported earlier, 2, 3 Interestingly, the initial values of antigenemia and DNAemia were not predictive for the subsequent kinetic pattern of CMV load. In agreement with an earlier study, 3 we also found relapsing episodes of active CMV infection to occur with comparable frequencies irrespective of whether the initial episode was either type A or type B.
Rising antigenemia during pre-emptive ganciclovir therapy has been postulated to occur in the face of an impaired CMV-specific T-cell response. However, this extent has not been proven. We defined earlier levels of pp65 and IE-1-specific IFNg CD8 þ and IFNg CD4 þ T cells providing protection against the development of viremic CMV infection (41 IFNg CD8 þ cell/ml and 41.2 IFNg CD4 þ T cells/ml). 8 Comparable levels of pp65-specific IFNg or TNFa-producing CD8 þ T cells (range, 1-5 cells/ml) and IFNg/IL-2-producing CD4 þ T cells (1 cell/ml) conferring protection against CMV antigenemia or DNAemia have been reported earlier. [15] [16] [17] [18] In this study, we enumerated peripheral levels of these T-cell subsets, both before and after the initiation of pre-emptive antiviral treatment, in a number of type A and type B episodes. Our data indicated that an early expansion of CMV pp65 and IE-1-specific IFNg CD8
þ and IFNg CD4 þ T-cell subsets in response to viral replication was associated with declining levels of antigenemia and DNAemia during antiviral therapy. Significant increases in the numbers of both IFNg subsets were seen at a median of 16.5 days after initiation of therapy. It is likely that this cell expansion might have been detected earlier had immunological monitoring been conducted with the same periodicity as virological monitoring. Unfortunately, this was not possible in this study. In contrast, a lack of prompt expansion of both T-cell populations, in particular the IFNg CD8 þ T-cell subset, was related to the occurrence of episodes with rising levels of antigenemia and DNAemia during therapy. In these episodes, an eventual expansion of both T-cell subsets was associated with control of CMV replication, whereas persistence of antigenemia and DNAemia (in two episodes) was related to a failure to do so.
Relapsing infections developed after 6 out of the 24 episodes (two type A and four type B) for which immunological data were available. Post-treatment cell counts of IFNg CD8
þ and IFNg CD4 þ T cells in these six episodes were below protective threshold values. 8 The number of CMV-specific functional cells at that time point might have been sufficient to control CMV replication in the presence of antivirals, but insufficient to protect from subsequent CMV reactivation in the absence of antiviral treatment.
Idiosyncratic variations of antiviral pharmacokinetics as well as the emergence of ganciclovir-resistant mutants may also be the cause of rising viral load during antiviral therapy. The latter phenomenon, however, has been shown to be a rare event in the allo-SCT setting, at least in treatment-naı¨ve patients. 2, 3, 5 Our data fully support this assumption. Development of ganciclovir resistance was observed in 2 out of 12 episodes with rising levels of antigenemia subject to analysis. In both cases, patients had received long courses of antiviral therapy and were unable to consistently expand CMV-specific IFNg CD8
þ and IFNg CD4 þ T cells in response to viral replication. Therapeutic interventions based on the assessment of CMV-specific T-cell immunity have been shown to lead to a more targeted use of antiviral therapy, 19 although clinical validation of this strategy requires further studies. In line with this study, our data suggest that frequent monitoring for CMV pp65 and IE-1-specific IFNg CD8 þ and IFNg CD4 þ T cells after initiation of pre-emptive antiviral therapy may be ancillary to routine virological surveillance for making optimal therapeutic decisions.
